Pharmaceutical composition for preventing or treating allergic skin diseases or pruritus
Patent Information
- Application Number
- MYPI2025004930
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-16
- Filing Date
- 2024-02-23
- Publication Date
- 2024-08-27
AI Technical Summary
Current treatments for atopic dermatitis, particularly in infants and young children, are inadequate due to the lack of effective diagnostic methods and suitable therapies, leading to prolonged and deepened disease progression, as existing treatments like steroids and immunosuppressants have limitations and cannot be prescribed for young patients.
A pharmaceutical composition containing ABT-751 or TN-16 as an active ingredient, which enhances filaggrin expression to improve skin barrier function and moisturizing effects, thereby effectively treating and preventing allergic skin diseases such as atopic dermatitis by increasing filaggrin expression and reducing inflammatory responses.
The composition significantly improves skin barrier function, reduces skin itching, and shows excellent therapeutic effects in treating and preventing allergic skin diseases by enhancing filaggrin expression and skin moisturizing, effectively addressing the limitations of existing treatments for atopic dermatitis.
Smart Images

Figure PI2025004930_DRAWING_001 
Figure PI2025004930_DRAWING_002 
Figure PI2025004930_DRAWING_003
Abstract
Description
Pharmaceutical composition for the prevention or treatment of allergic skin disease or skin itching
[0001] The present invention relates to a pharmaceutical composition for preventing or treating allergic skin disease or skin itching, and more particularly, to a pharmaceutical composition for preventing or treating allergic skin disease or skin itching containing ABT-751 or TN-16 as an active ingredient, a cosmetic composition for preventing or improving allergic skin disease or skin itching containing ABT-751 or TN-16 as an active ingredient, and a cosmetic composition for moisturizing the skin containing ABT-751 or TN-16 as an active ingredient.
[0002] Atopic dermatitis is a chronic and recurrent inflammatory skin disease that usually begins in infancy or childhood. It is a disease with a large number of patients, with an estimated 150 million patients in nine countries around the world, including the United States, the United Kingdom, and China. The related treatment market is expected to grow to approximately KRW 8 trillion by 2025.
[0003] In Korea, the number of patients receiving treatment for atopic dermatitis reaches 1 million each year, and the incidence rate is particularly high in infants and toddlers, with infants and toddlers aged 0-4 accounting for nearly 30% of the total, and children under 9 years of age accounting for half of the total.
[0004] The increasing prevalence of atopic dermatitis both domestically and internationally is due in part to its high incidence, but also to the lack of accurate diagnostic methods and appropriate treatments. Currently, atopic dermatitis is primarily diagnosed through medical history or physical examination, and treatments typically involve steroids or immunosuppressants, regardless of the underlying cause. While immunosuppressants have relatively mild side effects, they cannot be prescribed to infants and young children under two years of age, who have a particularly high incidence of the disease. This delays the timing of early treatment in infants and young children, who desperately need it, and can lead to the prolonged and worsening of the disease.
[0005] Although antibody treatments are currently being developed by global pharmaceutical companies, they can only be prescribed to severely ill patients aged 12 years or older, making them ineffective in treating infants and young children. Therefore, there is an urgent need to find a fundamental solution to this issue.
[0006] The research team completed the present invention by confirming that colchicine not only enhances the skin's inherent barrier function and increases moisture retention by regulating the expression level of filaggrin in the skin, but also exhibits disease prevention, treatment, and improvement effects in an atopic dermatitis model.
[0007] In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating allergic skin disease or skin itching containing ABT-751 or TN-16 as an active ingredient, a cosmetic composition for preventing or improving allergic skin disease or skin itching containing ABT-751 or TN-16 as an active ingredient, and a cosmetic composition for moisturizing the skin containing ABT-751 or TN-16 as an active ingredient.
[0008] The present invention provides a pharmaceutical composition for preventing or treating allergic skin disease or pruritus, containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient.
[0009] [Chemical Formula I]
[0010]
[0011] [Chemical Formula II]
[0012]
[0013] In one example of the present invention, the allergic skin disease may be atopic dermatitis or contact dermatitis.
[0014] In one example of the present invention, the allergic skin disease may be atopic dermatitis.
[0015] In one example of the present invention, the pharmaceutical composition may be administered by skin application.
[0016] In one example of the present invention, the atopic dermatitis may be due to decreased expression of filaggrin.
[0017] In one example of the present invention, when the decrease in expression of filaggrin is 5.0% or more compared to a normal person, the pharmaceutical composition may be administered to the patient.
[0018] In one example of the present invention, the pharmaceutical composition may be in any one dosage form selected from the group consisting of ointments, creams, lotions, gels, topical solutions, pastes, liniments, and aerosols.
[0019] In addition, the present invention provides a cosmetic composition for preventing or improving allergic skin disease or skin itching, which contains a compound represented by the following chemical formula I or chemical formula II as an active ingredient.
[0020] In one example of the present invention, the cosmetic composition may be in any one formulation selected from the group consisting of a solution, an external ointment, a cream, a foam, a nourishing toner, an emollient toner, a pack, an emollient, a milky lotion, a makeup base, an essence, a soap, a liquid cleanser, a bathing agent, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleansing, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray.
[0021] In addition, the present invention provides a skin moisturizing cosmetic composition containing a compound represented by the following chemical formula I or chemical formula II as an active ingredient.
[0022] [Chemical Formula I]
[0023]
[0024] [Chemical Formula II]
[0025]
[0026] In addition, the present invention provides a skin moisturizing quasi-drug composition containing a compound represented by the following chemical formula I or chemical formula II as an active ingredient.
[0027] [Chemical Formula I]
[0028]
[0029] [Chemical Formula II]
[0030]
[0031] It was confirmed that the composition for preventing, improving, or treating atopic dermatitis according to the present invention effectively increases the expression of filaggrin in skin cells and improves the skin barrier function, thereby effectively improving or treating the symptoms of allergic skin diseases or skin itching, including atopic dermatitis, and exhibits an excellent skin moisturizing effect.
[0032] Figures 1a and 1b show the increase in filaggrin expression by ABT-751 and TN-16 treatment, respectively.
[0033] Figure 2 shows the increase in cell differentiation by ABT-751 treatment.
[0034] Figures 3a to 3c show the increase in filaggrin expression in HR-1 mouse skin by ABT-751 (a, b) and TN-16 (c) treatment, respectively.
[0035] Figures 4a to 4d show the reduction in skin water loss and increase in skin barrier index of HR-1 mice by application of 4% formulations of ABT-751 (a, b) and TN-16 (c, d), respectively.
[0036] The present invention will be described in detail with reference to the attached tables and drawings below.
[0037] If drawings are included, they are provided as examples to ensure that the spirit of the present invention is fully conveyed to those skilled in the art. Therefore, the present invention is not limited to the drawings presented and may be embodied in other forms, and the drawings may be exaggerated to clarify the spirit of the present invention.
[0038] In this case, if there is no other definition in the technical and scientific terms used, they have the meaning commonly understood by a person of ordinary skill in the technical field to which this invention belongs, and the description of known functions and configurations that may unnecessarily obscure the gist of the present invention in the following description and attached drawings are omitted.
[0039] Additionally, the singular forms used in the specification of the present invention may be intended to include the plural forms as well, unless the context specifically indicates otherwise.
[0040] In addition, units used in the specification of the present invention without special mention are based on weight, and for example, units of % or ratio mean weight% or weight ratio.
[0041] Furthermore, in the specification of the present invention, the expression “comprises” is an open description equivalent to expressions such as “includes,” “contains,” “has,” or “is characterized by,” and does not exclude additional unrecited elements, materials, or processes. Furthermore, the expression “consists substantially of…” means that other unrecited elements, materials, or processes may be present together with the specified elements, materials, or processes in an amount that does not significantly affect at least one basic and novel technical idea of the invention to an unacceptable degree. Furthermore, the expression “consists of” means that only the recited elements, materials, or processes are present.
[0042] As used herein, the terms "component", "composition", "composition of compounds", "compound", "drug", "pharmaceutically active agent", "active agent", "cure", "treatment", "treatment" or "medicine" are used interchangeably to mean a compound or composition of compounds or substances that, when administered to a subject (human or animal), induces a desired pharmacological and / or physiological effect by local and / or systemic action.
[0043] The terms "treatment" or "treatment" (as well as their different forms) as used herein encompass preventive (e.g., prophylactic treatment), curative, or palliative treatment. The term "treating," as used herein, encompasses alleviating or reducing at least one adverse or negative effect or symptom of a condition, disease, or disorder. The terms "prevention," "improvement," and "treatment" as used herein should be interpreted in the broadest sense, where "prevention" means preventing the development of one or more of the clinical symptoms of a disease in a patient who may be exposed to or susceptible to the disease but who has not yet experienced or manifested symptoms of the disease. "Treatment" means any action that arrests or reduces the development of a disease or one or more of its clinical symptoms.
[0044] In the present invention, “sample” or “specimen” refers to an object for analysis and is used with the same meaning throughout the specification.
[0045] The present invention provides a pharmaceutical composition for preventing or treating allergic skin disease or pruritus, containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient.
[0046] [Chemical Formula I]
[0047]
[0048] [Chemical Formula II]
[0049]
[0050] The above compound I is a compound with CAS registry number 141430-65-1, ABT-751 (N-[2-[(4-Hydroxyphenyl)amino]pyridin-3-yl]-4-methoxybenzenesulfonamide).
[0051] ABT-751 is an oral anticancer drug developed as an antimitotic agent containing a sulfonamide. It exhibits antitumor activity against a wide range of tumor cells and was developed as a treatment for breast cancer and non-small cell lung cancer, but development was subsequently discontinued.
[0052] The above compound II is a compound with CAS registry number 33016-12-5, TN-16 (3-[1-(phenylamino)ethylidene]-5-(phenylmethyl)-2,4-pyrrolidinedione).
[0053] TN-16 is a novel microtubule inhibitor with antitumor activity. It was synthesized by modifying tenuazonic acid (3-acetyl-5-sec-butyltetramic acid), a natural antibiotic isolated and characterized from cultures of Alternaria tenuis. In 1967, TN-16 was discovered to possess potent anticancer properties, but subsequent studies failed to identify a more potent agent. In 1983, it was discovered that TN-16's mechanism of action is to inhibit microtubule formation, acting by binding to a sensitive site. The structure of TN-16 is similar to that of cytochalasin B, a canonical actin polymerization inhibitor, and it is known to induce cell cycle arrest at the M phase and inhibit the cytotoxicity of T lymphocytes and natural killer cells.
[0054] In the present invention, pharmaceutically acceptable salts refer to salts commonly used in the pharmaceutical industry, and examples thereof include inorganic ion salts manufactured with calcium, potassium, sodium and magnesium, inorganic acid salts manufactured with hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, iodic acid, perchloric acid and sulfuric acid, organic acid salts manufactured with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid and hydroiodic acid, sulfonic acid salts manufactured with methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and naphthalenesulfonic acid, glycine, Examples thereof include, but are not limited to, amino acid salts manufactured from arginine, lysine, etc., and amine salts manufactured from trimethylamine, triethylamine, ammonia, pyridine, picoline, etc.
[0055] According to the results of one embodiment of the present invention, the pharmaceutical composition not only improves the skin barrier function by increasing the expression level of filaggrin, which is highly related to the development of allergic skin disease, and increasing the skin moisturizing effect, but also has an excellent effect in the prevention and treatment of allergic skin disease, pruritus, or both through the action effect of regulating the inflammatory response of allergic skin disease and reducing skin itching.
[0056] Allergic skin diseases refer to pathological symptoms caused by allergic reactions mediated by mast cell activation, such as mast cell degranulation. Representative examples of such allergic skin diseases include atopic dermatitis and contact dermatitis.
[0057] Pruritus is a disease that includes itching caused by a decrease in antibacterial power and deterioration of barrier function due to a decrease in lipid content in the stratum corneum of the skin, or itching caused by external stimuli such as temperature changes, chemical substances, and electrical stimulation.
[0058] In the present invention, the term “anti-allergic” is used to mean improvement (alleviation of symptoms), treatment, and prevention (inhibition or delay of onset) of allergic skin diseases.
[0059] The aforementioned allergic skin disease may be, for example, atopic dermatitis, which presents with symptoms such as dry, eczematous skin and papules. Epidermal hyperplasia, epidermal proliferation, and accumulation of lymphocytes and mast cells are observed in lesion samples from atopic patients. Patients with atopic dermatitis may experience severe itching, which induces inflammation of the skin lesions and further worsens clinical symptoms.
[0060] The skin, anatomically located at the outermost layer of the body, protects the body from the external environment by blocking the direct inflow of pathogenic microorganisms, viruses, and chemicals in the air, and performs an important barrier function that prevents excessive loss of body moisture. Skin tissue is structured in layers: the basal layer, the spinous and granular layer, and the cornified layer. Each layer has a well-known specific expression marker. Among them, keratin 1 (K1) and keratin 10 (K10) are expressed in the differentiated layer, and filaggrin is expressed in the uppermost epidermis, including the stratum corneum. They are one of the major proteins essential for the formation of the skin's unique barrier function as described above.
[0061] Recently, a correlation between atopic dermatitis and the above-mentioned filaggrin gene abnormality has been revealed in patients with atopic dermatitis, such as the above-mentioned patients. In Europe, mutations in the filaggrin gene have been detected in more than half of all atopic patients. In Japan, mutations in the filaggrin gene have also been found in more than 25% of atopic patients, and in several Asian countries, including China and Korea, mutations in the filaggrin gene have been detected in patients with dermatitis, including atopic dermatitis. It has been reported that these filaggrin gene abnormalities lead to decreased expression of the filaggrin protein in the skin, loss of skin barrier function, and facilitate the penetration of antigens such as allergic irritants, thereby developing dermatitis. In fact, patients with filaggrin abnormalities among atopic dermatitis are very prone to progressing to allergic diseases such as asthma and rhinitis, and therefore, the development of diagnostic methods and therapeutics that can determine the presence or absence of filaggrin gene abnormalities is required.
[0062] The above atopic dermatitis may be caused by a decrease in the expression of filaggrin, and if the decrease in the expression of filaggrin is 5.0% or more compared to a normal person, the pharmaceutical composition may be administered to the patient.
[0063] In a specific embodiment of the present invention, the compound represented by the above chemical formula I enhances the expression of filaggrin and enhances the moisturizing effect of the skin, thereby exhibiting excellent improvement effects in terms of the skin barrier index and the overall skin index. In addition, in an allergic skin disease model, it not only significantly suppresses the inflammatory response, but also suppresses epidermal hyperplasia, epidermal proliferation, etc., regulates inflammatory cytokines, and reduces skin itching, thereby exhibiting excellent prevention, treatment, and improvement effects on allergic skin disease and / or pruritus. Here, the inflammatory cytokine refers to a cytokine that induces an inflammatory response occurring in the body, and is used in a conventional sense in the technical field to which the present invention pertains. For example, IL-2, IL-4, and IL-13 can act as inflammatory cytokines in inducing allergic skin disease.
[0064] For example, if the expression of filaggrin is reduced by 5.0% or more, preferably 5.3% or more, and more preferably 5.6% or more compared to a normal person, the patient can be determined to be suffering from atopic dermatitis, and accordingly, the pharmaceutical composition according to the present invention can be administered to the patient for the treatment of atopic dermatitis.
[0065] The above pharmaceutical composition may further comprise, in addition to containing the compound represented by the above chemical formula I or a pharmaceutically acceptable salt thereof, an appropriate carrier, excipient and diluent commonly used in pharmaceutical compositions.
[0066] Carriers, excipients and diluents that may be included in the above composition include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil. When formulating the above composition, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants and surfactants.
[0067] The above pharmaceutical composition can be formulated and used in various forms according to conventional methods, and when formulated as a transdermal agent, suitable formulations include, but are not limited to, ointments, creams, lotions, gels, topical solutions, pastes, liniments, and aerosols.
[0068] In addition to the carrier described above, the pharmaceutical composition according to the present invention may further include a preservative, a stabilizer, a wetting agent, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic pressure regulator, an antioxidant, etc.
[0069] Formulation of pharmaceutical compositions is well known in the art, and reference can be made to references such as Remington's Pharmaceutical Sciences (19th ed., 1995), which are incorporated herein by reference.
[0070] The pharmaceutical composition according to the present invention can be administered in a pharmaceutically effective amount.
[0071] In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined according to the type and severity of the patient's disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the duration of treatment, the concurrently used drugs, and other factors well known in the medical field. The pharmaceutical composition according to the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.
[0072] The pharmaceutical composition of the present invention can be administered to a subject via various routes. For example, the pharmaceutical composition can be administered in various oral and parenteral dosage forms. When formulated, the composition can be prepared using commonly used excipients. Preferably, the composition of the present invention can be used as a topical preparation for skin application as a parenteral preparation. The route of administration of the pharmaceutical composition of the present invention is determined by the type of drug as the active ingredient, along with various related factors such as the disease to be treated, the route of administration, the patient's age, sex, and weight, and the severity of the disease.
[0073] In addition, the present invention provides a cosmetic composition for preventing or improving allergic skin disease or skin itching, which contains a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient.
[0074] [Chemical Formula I]
[0075]
[0076] [Chemical Formula II]
[0077]
[0078] The above cosmetic composition may be in any one formulation selected from the group consisting of a solution, an external ointment, a cream, a foam, a nourishing toner, an emollient toner, a pack, an emollient, an emulsion, a makeup base, an essence, a soap, a liquid cleanser, a bath additive, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleansing, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.
[0079] In addition, the cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers that are blended with general skin cosmetics, and may appropriately blend conventional ingredients such as oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc., but is not limited thereto.
[0080] The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
[0081] When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or a mixture thereof may be used as a carrier component.
[0082] When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included.
[0083] When the formulation of the invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil can be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan can be used.
[0084] When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.
[0085] When the formulation of the present invention is soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. can be used as carrier components.
[0086] When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcositate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.
[0087] The cosmetic composition according to the present invention may contain colchicine in an amount of 0.01 to 20 wt% based on the total weight of the composition.
[0088] In addition, the present invention provides a skin moisturizing cosmetic composition containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient.
[0089] [Chemical Formula I]
[0090]
[0091] [Chemical Formula II]
[0092]
[0093] The above skin moisturizing may mean increasing the moisture content of the skin and maintaining the moist state, and the skin moisturizing cosmetic composition according to the present invention has an excellent skin moisturizing effect that suppresses or reduces the loss of skin moisture, and exhibits an excellent skin moisturizing effect by controlling the expression of factors such as filaggrin, involucrin, and loricrin, which are moisturizing-related factors.
[0094] In addition, the present invention provides a skin moisturizing quasi-drug composition containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient.
[0095] [Chemical Formula I]
[0096]
[0097] [Chemical Formula II]
[0098]
[0099] The above-mentioned pharmaceutical composition is a pharmaceutical composition for the purpose of moisturizing the skin.
[0100] The above quasi-drugs refer to products that are used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals, and have a milder effect than drugs. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are products excluding those used for the purpose of drugs, and may include, but are not limited to, fiber and rubber products used for the treatment or prevention of diseases of humans or animals, products that have a mild or no direct effect on the human body, are not instruments or machines or similar items, and sterilizers and insecticides for preventing infectious diseases.
[0101] The type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may preferably be a disinfectant, a shower foam, a gargle, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.
[0102] When the composition of the present invention is included in an over-the-counter drug for skin moisturizing purposes, the composition may be used as is or in combination with other over-the-counter drug ingredients, and may be used appropriately according to a conventional method. The mixing amount of the active ingredients may be appropriately determined depending on the intended use, and the over-the-counter drug composition according to the present invention may contain the compound represented by the above chemical formula I or chemical formula II in an amount of 0.01 to 20 wt% based on the total weight of the composition.
[0103] The present invention also provides a method for treating allergic skin disease or pruritus, comprising administering to a patient a pharmaceutical composition containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof.
[0104] [Chemical Formula I]
[0105]
[0106] [Chemical Formula II]
[0107]
[0108] The above treatment method may be administered to a patient through, for example, a) measuring the patient's filaggrin expression level; and b) determining that the patient needs to be administered the pharmaceutical composition if the filaggrin expression level is reduced by 5.0% or more compared to a normal person; but is not limited thereto, and the amount and administration cycle of the pharmaceutical composition administered to the patient may vary depending on the amount of reduced filaggrin, and according to an embodiment of the present invention, for example, it may be administered once a day for 1 to 4 weeks at a concentration of 0.5 to 2.5 μM, but is not limited thereto.
[0109]
[0110] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0111]
[0112] [Materials, reagents, strains, and devices, etc.]
[0113] - The human epidermal cell line (NHEK) is a human fetal keratinocyte cell line, and was obtained from ATCC.
[0114] These cells were obtained through primary culture and were used to confirm intracellular biochemical changes caused by ABT-751 or TN-16 under normal conditions, not disease conditions.
[0115] - Laboratory animals: hos:HR-1 (hairless) mice have the advantage of being able to conduct skin-related research by directly applying drugs to the skin or inducing skin diseases with chemical or biological allergens because they have no hair.
[0116] Additionally, the skin thickness at 8-10 weeks of age is approximately 0.4 mm, similar to human skin, making it useful for studying the pathogenesis of skin diseases and identifying biochemical changes within skin tissue.
[0117]
[0118] [Example 1]
[0119] 1.1 RNA extraction and measurement of filaggrin expression using RT-qPCR
[0120] Human epidermal cell lines (NHEK) or mouse skin tissues treated with ABT-751, TN-16, or control samples were lysed using TRI reagent (MRC), and intracellular RNA was extracted using the Rneasy Mini Kit (Qiagen).
[0121] The extracted RNA was reverse-transcribed using the ImProm-II TM Reverse Transcription Kit (Promega) to synthesize cDNA, and the amount of filaggrin was measured by quantitative PCR (qPCR) using a Real-Time PCR Detection System (Bio-Rad, CFX96).
[0122] 1-2. Protein extraction and Western blot
[0123] A portion of the collected tissue was homogenized using a tissue homogenizer (Daehan Science), lysed using a cell lysis buffer (RIPA buffer, Invitrogen), centrifuged using a centrifuge (Labogene), and the supernatant was transferred to a new tube and used as a protein sample.
[0124] 30 μg of protein sample was loaded onto a 4% to 12% gradient PAGE gel (Invitrogen), and SDS-PAGE was performed using a running buffer (Invitrogen) and an electrophoresis machine (Bio-Rad) to separate proteins by molecular weight.
[0125] The separated proteins were transferred to a PVDF film (Bio-Rad) and then blocked with 5% blocking solution (Skim milk; BD).
[0126] The thin film was reacted with filaggrin antibody (Santa Cruz) or GAPDH antibody (Abcam) for 16 hours, washed, and then reacted with secondary antibody for 1 hour and washed.
[0127] After reacting the protein with ECL solution (Thermo Fisher), the reaction was detected using a luminescence reaction measuring device (Fusion Solo, Vilber).
[0128]
[0129] [Test Example 2] Skin Barrier Function Test
[0130] Two hours after application of ABT-751 or TN-16, the skin moisture loss, skin barrier index, and overall index of the application area were measured and recorded for three weeks using a precision measuring device (Courage-khazaka electronic GmbH, MPA10).
[0131]
[0132] [Example 1] Filaggrin expression and cell differentiation in human epidermal cell lines treated with ABT-751 or TN-16
[0133] ABT-751 and TN-16 were each treated to cultured human epidermal keratinocyte (NHEK) cell lines, and the expression level of filaggrin was measured and changes in cell differentiation were confirmed.
[0134] ABT-751 and TN-16 were treated with NHEK at concentrations of 0, 0.5, 1.0, and 2.5 μM, respectively, and the filaggrin expression level and cell differentiation were observed 24 hours after treatment.
[0135] The results are shown in Figures 1 and 2.
[0136] From this, it was confirmed that the amount of filaggrin expression increased in a concentration-dependent manner depending on ABT-751 and TN-16 treatment (see Figures 1a and 1b), and it was confirmed that the degree of cell differentiation was significantly increased in the ABT-751 treatment group compared to the ABT-751 untreated group (control group) (see Figure 2).
[0137]
[0138] [Example 2] Filaggrin expression level and cell differentiation in animal cells treated with ABT-751 or TN-16
[0139] Equal amounts of 0, 1, 2, and 4% formulations of ABT-751 and TN-16 were applied to the dorsal skin of hairless hos:HR-1 mice (hereinafter referred to as HR-1 mice) once a day for 3 weeks.
[0140] After each application, skin moisture loss and skin barrier index were measured using the method of the above test example.
[0141] After two weeks of application, HR-1 mice were euthanized in a carbon dioxide chamber, and dorsal skin tissues were collected.
[0142] 2-1 Measurement of filaggrin expression level
[0143] RNA and protein were extracted from skin tissues to which ABT-751 or TN-16 was applied, respectively, using the method of the above test example, and the amount of filaggrin expression was measured, and the results are shown in Fig. 3.
[0144] From this, it was confirmed that the expression level of filaggrin in skin tissue increased in a concentration-dependent manner after application of the remaining formulations of ABT-751 or TN-16 compared to the control group (0% formulation ABT-751 or 0% formulation TN-16) (see Figures 3a to 3c).
[0145] 2-2. Measurement of skin moisture loss and skin barrier index
[0146] The results of measuring skin moisture loss and skin barrier index after applying the control group (0% formulation ABT-751 or 0% formulation TN-16) and 4% formulation ABT-751 or TN-16, respectively, are shown in Figure 4.
[0147] From this, it was confirmed that by applying 4% formulation of ABT-751 or TN-16, the skin moisture loss of the application area was reduced and the skin barrier index was increased in HR-1 mice (see Figures 4a to 4d).
[0148] In particular, it was confirmed that as the number of days of application passed, the degree of decrease in skin moisture loss and the degree of increase in skin barrier index increased.
[0149] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A pharmaceutical composition for preventing or treating allergic skin disease or pruritus, containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula I] [Chemical Formula II] 2. In paragraph 1, The above allergic skin disease is atopic dermatitis or contact dermatitis, a pharmaceutical composition for preventing or treating allergic skin disease or skin itching.
3. In paragraph 1, The above allergic skin disease is atopic dermatitis, a pharmaceutical composition for preventing or treating allergic skin disease or skin itching.
4. In paragraph 1, The above pharmaceutical composition is a pharmaceutical composition for preventing or treating allergic skin disease or itchy skin, which is administered by skin application.
5. In paragraph 1, A pharmaceutical composition for preventing or treating allergic skin disease or skin itching, wherein the above atopic dermatitis is caused by decreased expression of filaggrin.
6. In paragraph 5, A pharmaceutical composition for preventing or treating allergic skin disease or pruritus, wherein the pharmaceutical composition is administered to a patient when the expression of the above filaggrin is reduced by 5.0% or more compared to a normal person.
7. In paragraph 1, A pharmaceutical composition for preventing or treating allergic skin disease or skin itching, wherein the pharmaceutical composition is in any one formulation selected from the group consisting of ointments, creams, lotions, gels, external solutions, pastes, liniments, and aerosols.
8. A cosmetic composition for preventing or improving allergic skin disease or skin itching, containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula I] [Chemical Formula II] 9. In paragraph 8, The above cosmetic composition is a cosmetic composition for preventing or improving allergic skin disease or skin itching, which is in any one formulation selected from the group consisting of a solution, an external ointment, a cream, a foam, a nourishing toner, an emollient toner, a pack, an emollient, an emulsion, a makeup base, an essence, a soap, a liquid cleanser, a bath agent, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleansing, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray.
10. A cosmetic composition for moisturizing the skin, containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula I] [Chemical Formula II] 11. A skin moisturizing quasi-drug composition containing a compound represented by the following chemical formula I or chemical formula II or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula I] [Chemical Formula II]
